{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T03:52:29Z","timestamp":1766461949751,"version":"3.48.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01374-x","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:19:09Z","timestamp":1766413149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic Artery Infusion Pump Therapy for Intrahepatic Cholangiocarcinoma: Indications and Outcomes"],"prefix":"10.1007","volume":"56","author":[{"given":"Jason","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"5","key":"1374_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261\u201380. https:\/\/doi.org\/10.1038\/nrgastro.2016.51.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1374_CR2","doi-asserted-by":"publisher","unstructured":"Connor AA, Kodali S, Abdelrahim M, Javle MM, Brombosz EW, Ghobrial RM. Intrahepatic cholangiocarcinoma: the role of liver transplantation, adjunctive treatments, and prognostic biomarkers. Front Oncol. 2022;12\u20132022. https:\/\/doi.org\/10.3389\/fonc.2022.996710.\u00a0","DOI":"10.3389\/fonc.2022.996710"},{"issue":"1","key":"1374_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","volume":"16","author":"KJ Yao","year":"2016","unstructured":"Yao KJ, Jabbour S, Parekh N, Lin Y, Moss RA. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics database. BMC Gastroenterol. 2016;16(1):117. https:\/\/doi.org\/10.1186\/s12876-016-0527-z.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"1374_CR4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.21037\/jgo-24-165","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Alsaraf Y, Bandaru SS, Lyons S, Reap L, Ngo T, Yu Z, Yu Q. Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma. J Gastrointest Oncol. 2024;15(4):1777\u201388.","journal-title":"J Gastrointest Oncol"},{"key":"1374_CR5","unstructured":"Survival Rates for Bile Duct Cancer. (2025). Retrieved Aug 7 from https:\/\/www.cancer.org\/cancer\/types\/bile-duct-cancer\/detection-diagnosis-staging\/survival-by-stage.html"},{"issue":"11","key":"1374_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.hpb.2023.06.019","volume":"25","author":"PB Olthof","year":"2023","unstructured":"Olthof PB, Franssen S, van Keulen A-M, van der Geest LG, Hoogwater FJH, Coenraad M, van Driel LMJW, Erdmann JI, Mohammad NH, Heij L, Kl\u00fcmpen H-J, Tjwa E, van Valkenburg- L, Verheij J, Koerkamp G, B. Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma. HPB. 2023;25(11):1329\u201336. https:\/\/doi.org\/10.1016\/j.hpb.2023.06.019.","journal-title":"HPB"},{"key":"1374_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040739","author":"C Tsung","year":"2024","unstructured":"Tsung C, Quinn PL, Ejaz A. Management of intrahepatic cholangiocarcinoma: a narrative review. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16040739.","journal-title":"Cancers (Basel)"},{"key":"1374_CR8","unstructured":"Biliary Tract Cancers. (2025). NCCN. Retrieved Aug 7 from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf"},{"issue":"8","key":"1374_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, He AR, Bouattour M, Okusaka T, Qin S, Chen L-T, Kitano M, Lee C-k, Kim JW, Chen M-H, Suksombooncharoen T, Ikeda M, Lee MA, Chen J-S, Potemski P, Burris HA III, Ostwal V, Tanasanvimon S, Morizane C, Valle JW. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"14","key":"1374_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"issue":"2","key":"1374_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jnci\/djz071","volume":"112","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, Manoharan P, Palmer D, Bridgewater J, Valle JW. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and \u2013\u200903 clinical trials. J Natl Cancer Inst. 2020;112(2):200\u201310. https:\/\/doi.org\/10.1093\/jnci\/djz071.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1374_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/cncr.30488","volume":"123","author":"S Yamashita","year":"2017","unstructured":"Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, et al. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients. Cancer. 2017;123(8):1354\u201362. https:\/\/doi.org\/10.1002\/cncr.30488.","journal-title":"Cancer"},{"issue":"1","key":"1374_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D\u2019Angelica M, DeMatteo RP, Fong Y, Schwartz L, Kemeny N, O\u2019Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, Jarnagin WR. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e318176c4d3.","journal-title":"Ann Surg"},{"issue":"8","key":"1374_CR14","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1245\/s10434-014-3649-y","volume":"21","author":"IT Konstantinidis","year":"2014","unstructured":"Konstantinidis IT, Do RKG, Gultekin DH, G\u00f6nen M, Schwartz LH, Fong Y, et al. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol. 2014;21(8):2675\u201383. https:\/\/doi.org\/10.1245\/s10434-014-3649-y.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"1374_CR15","doi-asserted-by":"publisher","first-page":"12272","DOI":"10.1002\/cam4.5925","volume":"12","author":"KC Soares","year":"2023","unstructured":"Soares KC, Jolissaint JS, McIntyre SM, Seier KP, G\u00f6nen M, Sigel C, Nasar N, Cercek A, Harding JJ, Kemeny NE, Connell LC, Koerkamp BG, Balachandran VP, D\u2019Angelica MI, Drebin JA, Kingham TP, Wei AC, Jarnagin WR. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival. Cancer Med. 2023;12(11):12272\u201384. https:\/\/doi.org\/10.1002\/cam4.5925.","journal-title":"Cancer Med"},{"issue":"5","key":"1374_CR16","first-page":"969","volume":"30","author":"C Breedis","year":"1954","unstructured":"Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969\u201377.","journal-title":"Am J Pathol"},{"key":"1374_CR17","unstructured":"Intera 3000 Hepatic Artery Infusion Pump Safety Information. Retrieved Aug 8 from https:\/\/www.interaoncology.com\/healthcare-professionals\/intera-3000-pump\/safety-information"},{"issue":"2","key":"1374_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/PPO.0b013e3181d7ea51","volume":"16","author":"MK Callahan","year":"2010","unstructured":"Callahan MK, Kemeny NE. Implanted hepatic arterial infusion pumps. Cancer J. 2010;16(2):142\u20139. https:\/\/doi.org\/10.1097\/PPO.0b013e3181d7ea51.","journal-title":"Cancer J"},{"issue":"2","key":"1374_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/op.23.00374","volume":"20","author":"D Rao","year":"2024","unstructured":"Rao D, Ellis CS, Kemeny N, Cercek A. Case-based clinical guidance on dosing and management of the hepatic artery infusion chemotherapy pump. JCO Oncol Pract. 2024;20(2):187\u201394. https:\/\/doi.org\/10.1200\/op.23.00374.","journal-title":"JCO Oncol Pract"},{"key":"1374_CR20","doi-asserted-by":"publisher","unstructured":"Atiq OT, Kemeny N, Niedzwiecki D, Botet J. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer. 1992;69(4):920\u20134. https:\/\/doi.org\/10.1002\/1097-0142(19920215)69:4%3C;920::aid-cncr2820690414%3E;3.0.co;2-y.","DOI":"10.1002\/1097-0142(19920215)69:4%3C;920::aid-cncr2820690414%3E;3.0.co;2-y"},{"issue":"4","key":"1374_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1067\/msy.2002.122374","volume":"131","author":"PA Clavien","year":"2002","unstructured":"Clavien PA, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery. 2002;131(4):433\u201342. https:\/\/doi.org\/10.1067\/msy.2002.122374.","journal-title":"Surgery"},{"issue":"9","key":"1374_CR22","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","volume":"20","author":"WR Jarnagin","year":"2009","unstructured":"Jarnagin WR, Schwartz LH, Gultekin DH, G\u00f6nen M, Haviland D, Shia J, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009;20(9):1589\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdp029.","journal-title":"Ann Oncol"},{"issue":"9","key":"1374_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/BF02557524","volume":"9","author":"PJ Allen","year":"2002","unstructured":"Allen PJ, Stojadinovic A, Ben-Porat L, Gonen M, Kooby D, Blumgart L, et al. The management of variant arterial anatomy during hepatic arterial infusion pump placement. Ann Surg Oncol. 2002;9(9):875\u201380. https:\/\/doi.org\/10.1007\/BF02557524.","journal-title":"Ann Surg Oncol"},{"key":"1374_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7195373","volume":"2020","author":"F Hahn","year":"2020","unstructured":"Hahn F, M\u00fcller L, M\u00e4hringer-Kunz A, Tanyildizi Y, Dos Santos DP, D\u00fcber C, et al. Distant metastases in patients with intrahepatic cholangiocarcinoma: does location matter? A retrospective analysis of 370 patients. J Oncol. 2020;2020:7195373. https:\/\/doi.org\/10.1155\/2020\/7195373.","journal-title":"J Oncol"},{"issue":"12","key":"1374_CR25","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.7150\/jca.19056","volume":"8","author":"W Wu","year":"2017","unstructured":"Wu W, He X, Andayani D, Yang L, Ye J, Li Y, et al. Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study [Research Paper]. J Cancer. 2017;8(12):2312\u20138. https:\/\/doi.org\/10.7150\/jca.19056.","journal-title":"J Cancer"},{"issue":"14","key":"1374_CR26","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1158\/1078-0432.Ccr-21-0412","volume":"27","author":"JS Jolissaint","year":"2021","unstructured":"Jolissaint JS, Soares KC, Seier KP, Kundra R, G\u00f6nen M, Shin PJ, et al. Intrahepatic cholangiocarcinoma with lymph node metastasis: treatment-related outcomes and the role of tumor genomics in patient selection. Clin Cancer Res. 2021;27(14):4101\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0412.","journal-title":"Clin Cancer Res"},{"key":"1374_CR27","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.hpb.2025.03.146","volume":"27","author":"A Dinerman","year":"2025","unstructured":"Dinerman A, Eade A, Monge C, Hannah C, Larrain C, Pu T, et al. Hepatic lymph node metastases predict survival for patients undergoing HAIP therapy for CRLM. HPB. 2025;27:S78. https:\/\/doi.org\/10.1016\/j.hpb.2025.03.146.","journal-title":"HPB"},{"issue":"1","key":"1374_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, Boerner T, Tan BR, Chou JF, G\u00f6nen M, Boucher TM, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):60\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3718.","journal-title":"JAMA Oncol"},{"key":"1374_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174217","author":"H Bourien","year":"2023","unstructured":"Bourien H, Pircher CC, Guiu B, Lamarca A, Valle JW, Niger M, et al. Locoregional treatment in intrahepatic cholangiocarcinoma: which treatment for which patient? Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15174217.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1374_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1245\/s10434-017-6110-1","volume":"25","author":"GP Wright","year":"2018","unstructured":"Wright GP, Perkins S, Jones H, Zureikat AH, Marsh JW, Holtzman MP, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a comparison of surgical resection with intra-arterial therapies. Ann Surg Oncol. 2018;25(1):83\u201390. https:\/\/doi.org\/10.1245\/s10434-017-6110-1.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1374_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29824","volume":"122","author":"IT Konstantinidis","year":"2016","unstructured":"Konstantinidis IT, Koerkamp BG, Do RKG, G\u00f6nen M, Fong Y, Allen PJ, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758\u201365.","journal-title":"Cancer"},{"issue":"2","key":"1374_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/jnci\/djae202","volume":"117","author":"D Cowzer","year":"2025","unstructured":"Cowzer D, Soares K, Walch H, G\u00f6nen M, Boucher TM, Do RKG, et al. Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy. J Natl Cancer Inst. 2025;117(2):279\u201386. https:\/\/doi.org\/10.1093\/jnci\/djae202.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1374_CR33","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1245\/s10434-022-11439-x","volume":"29","author":"JJ Holster","year":"2022","unstructured":"Holster JJ, Hassnaoui E, Franssen M, JNM S, de Jonge IJ, Mostert J, et al. Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2022;29(9):5528\u201338. https:\/\/doi.org\/10.1245\/s10434-022-11439-x.","journal-title":"Ann Surg Oncol"},{"key":"1374_CR34","doi-asserted-by":"publisher","unstructured":"Franssen S, Rousian M, Filipe WF, Buisman FE, Haaft BH E. A. t., Swijnenburg R-J, Mostert B, Mohammad NH, Hagendoorn J, Doukas M, Kl\u00fcmpen H-J, Homs MYV, Koerkamp BG. Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma\u2014PUMP-2 Trial.\u00a0J Clin Oncol\u00a00(0):JCO\u201325\u201300923. https:\/\/doi.org\/10.1200\/jco-25-00923","DOI":"10.1200\/jco-25-00923"},{"issue":"3_suppl","key":"1374_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2024.42.3_suppl.433","volume":"42","author":"S Franssen","year":"2024","unstructured":"Franssen S, Rousian M, Nooijen LE, Haaft BHEAt, Doukas M, Mohammad NH, et al. Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: a multicenter phase II trial. J Clin Oncol. 2024;42(3_suppl):433\u2013433. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.433.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1374_CR36","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cam4.299","volume":"3","author":"F Fiteni","year":"2014","unstructured":"Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, et al. Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 2014;3(6):1502\u201311. https:\/\/doi.org\/10.1002\/cam4.299.","journal-title":"Cancer Med"},{"issue":"10391","key":"1374_CR37","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"3","key":"1374_CR38","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.21037\/jgo-24-71","volume":"15","author":"JH Victory","year":"2024","unstructured":"Victory JH, Smith EC, Ryan CE, Lambdin J, Sarvestani AL, Friedman LR, et al. Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: a phase II trial protocol. J Gastrointest Oncol. 2024;15(3):1348\u201354. https:\/\/doi.org\/10.21037\/jgo-24-71.","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"1374_CR39","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/sla.0000000000005434","volume":"276","author":"JM Sharib","year":"2022","unstructured":"Sharib JM, Creasy JM, Wildman-Tobriner B, Kim C, Uronis H, Hsu SD, et al. Hepatic artery infusion pumps: a surgical toolkit for intraoperative decision-making and management of hepatic artery infusion-specific complications. Ann Surg. 2022;276(6):943\u201356. https:\/\/doi.org\/10.1097\/sla.0000000000005434.","journal-title":"Ann Surg"},{"issue":"6","key":"1374_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/00000658-198712000-00001","volume":"206","author":"AE Chang","year":"1987","unstructured":"Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206(6):685\u201393. https:\/\/doi.org\/10.1097\/00000658-198712000-00001.","journal-title":"Ann Surg"},{"issue":"5","key":"1374_CR41","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1245\/s10434-011-2102-8","volume":"19","author":"K Ito","year":"2012","unstructured":"Ito K, Ito H, Kemeny NE, Gonen M, Allen PJ, Paty PB, Fong Y, Dematteo RP, Blumgart LH, Jarnagin WR, D\u2019Angelica MI. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19(5):1609\u201317. https:\/\/doi.org\/10.1245\/s10434-011-2102-8.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1374_CR42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00000658-198508000-00007","volume":"202","author":"MM Kemeny","year":"1985","unstructured":"Kemeny MM, Battifora H, Blayney DW, Cecchi G, Goldberg DA, Leong LA, Margolin KA, Terz JJ. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg. 1985;202(2):176\u201381. https:\/\/doi.org\/10.1097\/00000658-198508000-00007.","journal-title":"Ann Surg"},{"key":"1374_CR43","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.hpb.2023.05.013","volume":"25","author":"CE Ryan","year":"2023","unstructured":"Ryan CE, Gregory SN, Teke M, Sarvestani AL, Remmert K, Lambdin JT, et al. Peribiliary gland injury by Floxuridine may be an early mechanistic insult en route to sclerosis. HPB. 2023;25:S2-3. https:\/\/doi.org\/10.1016\/j.hpb.2023.05.013.","journal-title":"HPB"},{"issue":"4","key":"1374_CR44","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/hep.30365","volume":"69","author":"IEM de Jong","year":"2019","unstructured":"de Jong IEM, Matton APM, van Praagh JB, van Haaften WT, Wiersema-Buist J, van Wijk LA, et al. Peribiliary glands are key in regeneration of the human biliary epithelium after severe bile duct injury. Hepatology. 2019;69(4):1719\u201334. https:\/\/doi.org\/10.1002\/hep.30365.","journal-title":"Hepatology"},{"issue":"6","key":"1374_CR45","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1084\/jem.194.6.809","volume":"194","author":"CG Lee","year":"2001","unstructured":"Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001;194(6):809\u201321. https:\/\/doi.org\/10.1084\/jem.194.6.809.","journal-title":"J Exp Med"},{"key":"1374_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay0152","author":"TY Jiang","year":"2020","unstructured":"Jiang TY, Pan YF, Wan ZH, Lin YK, Zhu B, Yuan ZG, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aay0152.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1374_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","volume":"38","author":"SK Radhakrishnan","year":"2010","unstructured":"Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, Deshaies RJ. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 2010;38(1):17\u201328. https:\/\/doi.org\/10.1016\/j.molcel.2010.02.029.","journal-title":"Mol Cell"},{"key":"1374_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.199200","author":"CM Larrain","year":"2025","unstructured":"Larrain CM, Victory JH, Desai PP, Friedman LR, Stepp H, Ashe R, et al. A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion. JCI Insight. 2025. https:\/\/doi.org\/10.1172\/jci.insight.199200.","journal-title":"JCI Insight"},{"issue":"9","key":"1374_CR49","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","volume":"20","author":"WR Jarnagin","year":"2009","unstructured":"Jarnagin WR, Schwartz LH, Gultekin DH, G\u00f6nen M, Haviland D, Shia J, D\u2019Angelica M, Fong Y, DeMatteo R, Tse A, Blumgart LH, Kemeny N. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009;20(9):1589\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdp029.","journal-title":"Ann Oncol"},{"issue":"3\u20134","key":"1374_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000324704","volume":"80","author":"NE Kemeny","year":"2011","unstructured":"Kemeny NE, Schwartz L, G\u00f6nen M, Yopp A, Gultekin D, D\u2019Angelica MI, et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results. Oncology. 2011;80(3\u20134):153\u20139. https:\/\/doi.org\/10.1159\/000324704.","journal-title":"Oncology"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01374-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T03:02:20Z","timestamp":1766458940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01374-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"type":"print","value":"1941-6628"},{"type":"electronic","value":"1941-6636"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"8 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}